Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas

Since their inception in the commercial market in the mid-twentieth century, sulfonylureas (SUs) have remained a therapeutic option in the management of type 2 diabetes (T2D). Despite their established glucose-lowering effects, there is no consensus among global experts and modern guidelines regardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Saleh, Yousef, Sabico, Shaun, Al-Furqani, Ahmed, Jayyousi, Amin, Alromaihi, Dalal, Ba-Essa, Ebtesam, Alawadi, Fatheya, Alkaabi, Juma, Hassanein, Mohamed, Al-Sifri, Saud, Saleh, Seham, Alessa, Thamer, Al-Daghri, Nasser M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342668/
https://www.ncbi.nlm.nih.gov/pubmed/33983614
http://dx.doi.org/10.1007/s13300-021-01059-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342668/
https://www.ncbi.nlm.nih.gov/pubmed/33983614
http://dx.doi.org/10.1007/s13300-021-01059-1

Ejemplares similares